TGFBR2
Overview
TGFBR2 (Transforming Growth Factor Beta Receptor 2) encodes the type II receptor of the TGF-beta signaling pathway. Inactivating mutations in TGFBR2 impair TGF-beta-mediated growth inhibition, promoting tumor progression. TGFBR2 is recurrently mutated in colorectal cancer (particularly microsatellite-unstable tumors), gastric cancer, and esophageal squamous cell carcinoma.
Alterations observed in the corpus
- Significantly mutated in ESCC (ESCC) in the TCGA esophageal carcinoma cohort (stes_tcga_pub, n=90 ESCC), identified by MutSigCV2.0 analysis. PMID:28052061
- GCB-selective CRISPR essential dependency in DLBCL PMID:28985567
Cancer types (linked)
- ESCC: TGFBR2 is a significantly mutated gene in ESCC; loss of TGF-beta signaling is a recurrent mechanism of tumor suppressor inactivation in this histology. PMID:28052061
Co-occurrence and mutual exclusivity
- No specific co-occurrence or mutual exclusivity pattern reported for TGFBR2 within ESCC molecular subtypes in the corpus.
Therapeutic relevance
- No direct targeted therapy for TGFBR2-mutant ESCC described in the corpus.
Open questions
- Whether TGFBR2 mutation enriches in specific ESCC subtypes (ESCC1/2/3) or correlates with prognosis requires further analysis of the TCGA ESCC dataset. PMID:28052061
Sources
This page was processed by entity-page-writer on 2026-05-15. - PMID:28985567
This page was processed by wiki-cli on 2026-05-15.